Stocks › CDNA
CareDx, Inc.
CDNA·Nasdaq·
United States·USD
$70.00
-1.92 (-2.67%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CDNA
CareDx, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CDNAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of CDNA by members of U.S. Congress · 14 on record
Whale Activity
Position changes in CDNA reported for 2026-09-30 by 329 institutional filers
- Increased88
- New96
- Held24
- Decreased86
- Closed22
- No prior filing13
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 4.9M | $316.7M | increased |
| STATE STREET CORP | 2.6M | $170.5M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $142.6M | decreased |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.1M | $133.9M | increased |
| Blue Water Life Science Advisors, LP | 1.7M | $113.1M | increased |
| ARK Investment Management LLC | 1.6M | $104.6M | decreased |
| BAMCO INC /NY/ | 1.5M | $97.5M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5M | $96.3M | increased |
| Divisadero Street Capital Management, LP | 1.4M | $92.3M | increased |
| Chevy Chase Trust Holdings, LLC | 1.4M | $87.9M | decreased |
| FRANKLIN TEMPLETON INC | 985.7K | $84.6M | increased |
| D. E. Shaw & Co., Inc. | 1.3M | $83.4M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by CDNA insiders, by quarter · Form 4
Recent Insider Transactions
1,282 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Riggsbee Richard BryanDirector · Director | Sale | −800 | $75.95 | $61K | Nov 16, 2026 | Form 4 ↗ |
| Riggsbee Richard BryanDirector · Director | Sale | −400 | $77.02 | $31K | Nov 16, 2026 | Form 4 ↗ |
| Riggsbee Richard BryanDirector · Director | Sale | −2,418 | $74.02 | $179K | Nov 16, 2026 | Form 4 ↗ |
| Riggsbee Richard BryanDirector · Director | Sale | −1,667 | $74.74 | $125K | Nov 16, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −800 | $78.78 | $63K | Nov 12, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −1,297 | $79.61 | $103K | Nov 12, 2026 | Form 4 ↗ |
| Goldberg MichaelDirector · Director | Sale | −8,024 | $79.32 | $636K | Nov 12, 2026 | Form 4 ↗ |
| Goldberg MichaelDirector · Director | Sale | −3,547 | $78.32 | $278K | Nov 12, 2026 | Form 4 ↗ |
| Goldberg MichaelDirector · Director | Sale | −2,229 | $79.85 | $178K | Nov 12, 2026 | Form 4 ↗ |
| Novack Jeffrey AdamSecretary and General Counsel | Sale | −900 | $83.33 | $75K | Nov 10, 2026 | Form 4 ↗ |
| Novack Jeffrey AdamSecretary and General Counsel | Sale | −2,996 | $80.47 | $241K | Nov 10, 2026 | Form 4 ↗ |
| Novack Jeffrey AdamSecretary and General Counsel | Sale | −200 | $81.05 | $16K | Nov 10, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −7,415 | $79.49 | $589K | Nov 5, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −6,897 | $78.59 | $542K | Nov 5, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −600 | $83.60 | $50K | Nov 5, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −3,403 | $80.38 | $274K | Nov 5, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −300 | $82.08 | $25K | Nov 5, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −28.3K | $76.55 | $2.2M | Nov 5, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −2,710 | $81.40 | $221K | Nov 5, 2026 | Form 4 ↗ |
| Kennedy KeithCFO & COO | Sale | −12.4K | $77.42 | $958K | Nov 5, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding CDNA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF ARK ETF Trust | 1.5M | $66.9M | 4.30% | Jul 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $44.3M | 0.00% | Jun 30, 2026 |
| BARON DISCOVERY FUND BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 1.4M | $39.1M | 2.14% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.3M | $38.2M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.1M | $32.6M | 0.30% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 560.8K | $24.5M | 0.07% | Jul 31, 2026 |
| Strategic Advisers U.S. Total Stock Fund Fidelity Rutland Square Trust II | 464.1K | $23.3M | 0.02% | Aug 31, 2026 |
| First Eagle Small Cap Opportunity Fund First Eagle Funds | 485.1K | $21.2M | 0.73% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 588.5K | $16.8M | 0.02% | Jun 30, 2026 |
| Column Small Cap Select Fund Trust for Professional Managers | 326.3K | $16.4M | 0.85% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CDNA's shares (CUSIP 14167L103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 2.6M shares5.1%
Nov 10, 2026 · ↗ - Baron Capital Management, Inc.SCHEDULE 13G/A · passive (13G) · 274.4K shares0.5%
Aug 14, 2026 · ↗ - Ronald BaronSCHEDULE 13G/A · passive (13G) · 1.9M shares3.8%
Aug 14, 2026 · ↗ - Baron Capital Group, Inc.SCHEDULE 13G/A · passive (13G) · 1.9M shares3.8%
Aug 14, 2026 · ↗ - BAMCO INC /NY/SCHEDULE 13G/A · passive (13G) · 1.7M shares3.2%
Aug 14, 2026 · ↗ - Neil GagnonSCHEDULE 13G/A · passive (13G) · 2.3M shares4.4%
Aug 7, 2026 · ↗ - Gagnon Advisors, LLCSCHEDULE 13G/A · passive (13G) · 408.8K shares0.8%
Aug 7, 2026 · ↗ - Gagnon Securities LLCSCHEDULE 13G/A · passive (13G) · 1.6M shares3.2%
Aug 7, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 2.5M shares4.8%
Aug 7, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 4.7M shares9.0%
Jul 27, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming caredx as client
Government Contracts
Federal awards to caredx · USAspending
$6.6MAwarded · 6 contracts on record
- Department of Veterans AffairsALLOSURE IN-HOME PATIENT TESTING$142K
Jan 15, 2027 · ↗ - Department of Veterans AffairsALLOSURE KIDNEY TEST$236K
Oct 19, 2022 · ↗ - Department of Veterans AffairsLAB TESTS FOR POST TRANSPLANT CARE.$1.6M
Apr 1, 2026 · ↗ - Department of Veterans AffairsTRANSPLANT TESTING KITS$2.5M
Sep 29, 2026 · ↗ - Department of Veterans AffairsGENETIC BLOOD TESTING FOR TRANSPLANT PATIENTS (ALLOMAP AND ALLOSURE)$1.0M
Sep 23, 2026 · ↗ - Department of Veterans AffairsALLOMAP AND ALLOSURE POST HEART TRANSPLANT REJECTION SURVEILLANCE TESTS SERVICES$1.1M
Mar 1, 2022 · ↗
U.S. Patents
Recent USPTO applications naming CareDx, Inc.
No USPTO patent applications found for CareDx, Inc..
Annual Financials
From CDNA's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $379.8M | $333.8M | $280.3M | $321.8M | $296.4M |
| Operating income | -$30.8M | $40.8M | -$203.4M | -$77.2M | -$29.7M |
| Net income | -$21.4M | $52.5M | -$190.3M | -$76.6M | -$30.7M |
| Diluted EPS | -$0.40 | $0.93 | -$3.54 | -$1.44 | -$0.59 |
| Operating cash flow | $42.0M | $38.0M | -$18.4M | -$25.2M | -$19.3M |
| Cash and equivalents | $65.4M | $114.7M | $82.2M | $89.9M | $348.5M |
| Total assets | $413.2M | $491.1M | $466.8M | $543.0M | $566.6M |
| Total liabilities | $110.1M | $112.6M | $205.5M | $112.1M | $100.7M |
| Shareholders' equity | $303.1M | $378.4M | $261.3M | $430.9M | $465.9M |
As CareDx, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in CDNA's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureOct 29, 2026
EDGAR ↗ - 8-K/A · Items 2.01, 9.01Acquisition or dispositionSep 16, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureJul 30, 2026
EDGAR ↗ - 8-K · Items 2.01, 7.01, 9.01Acquisition or disposition · Reg FD disclosureJul 7, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 15, 2026
EDGAR ↗
About CareDx, Inc.
From SEC EDGAR company records
Industry (SIC 8071)Services-Medical Laboratories
SectorHealthcare
HeadquartersBRISBANE, CA
IncorporatedDE
SEC CIK0001217234 ↗
Former namesXDx, Inc., EXPRESSION DIAGNOSTICS INC


